鼠李糖乳杆菌GG通过cGAS/STING依赖的I型干扰素改善免疫检查点阻断疗效
该研究在结直肠癌和黑色素瘤小鼠模型中评估口服鼠李糖乳杆菌GG(LGG)联合免疫检查点阻断(ICB)的抗肿瘤效果。结果显示活LGG增强抗PD-1疗效,增加肿瘤浸润树突状细胞(DC)和T细胞,并改变肠道菌群。机制上LGG通过DC中cGAS/STING/TBK1/IRF7轴诱导IFN-β,增强CD8+ T细胞交叉致敏。
要点
- 口服活LGG增强抗PD-1抗体对小鼠结直肠癌和黑色素瘤的抗肿瘤活性。
- LGG联合抗PD-1增加肿瘤浸润DC和T细胞,并富集特定肠道菌群。
- LGG通过DC中cGAS/STING/TBK1/IRF7轴诱导IFN-β,增强CD8+ T细胞交叉致敏。
核心结论
- 口服活LGG通过cGAS/STING依赖的I型干扰素增强抗肿瘤免疫,改善ICB疗效。
研究设计与样本
- 使用结直肠癌和黑色素瘤小鼠模型评估口服LGG联合ICB的疗效。
- 对肠道内容物进行全基因组鸟枪法宏基因组测序,对树突状细胞进行RNA测序。
- 通过系列体外和体内实验定义LGG介导抗肿瘤免疫的免疫学和分子机制。
主要发现
- 口服活LGG增强抗PD-1免疫治疗的抗肿瘤活性,增加肿瘤浸润DC和T细胞。
- 联合治疗使肠道微生物群落向鼠李糖乳杆菌和Bacteroides uniformis富集。
- 活LGG单用或联合抗PD-1触发DC产生I型干扰素,增强抗肿瘤CD8+ T细胞交叉致敏。
- cGAS或STING缺陷DC中IFN-β水平显著降低,表明cGAS/STING是LGG诱导IFN-β所必需。
- LGG通过cGAS/STING/TBK1/IRF7轴诱导DC产生IFN-β。
临床怎么用
- 为开发口服活LGG作为ICB联合抗肿瘤治疗提供实验依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Our goals were to evaluate the antitumour efficacy of Lactobacillus rhamnosus GG (LGG) in combination with immune checkpoint blockade (ICB) immunotherapies on tumour growth and to investigate the underlying mechanisms. DESIGN: We used murine models of colorectal cancer and melanoma to evaluate whether oral administration of LGG improves the efficacy of ICB therapies. We performed the whole genome shotgun metagenome sequencing of intestinal contents and RNA sequencing of dendritic cells (DCs). In a series of in vitro and in vivo experiments, we further defined the immunological and molecular mechanisms of LGG-mediated antitumour immunity. RESULTS: We demonstrate that oral administration of live LGG augmented the antitumour activity of anti-programmed cell death 1 (PD-1) immunotherapy by increasing tumour-infiltrating DCs and T cells. Moreover, the combination treatment shifted the gut microbial community towards enrichment in Lactobacillus murinus and Bacteroides uniformis, that are known to increase DC activation and CD8+tumour recruitment. Mechanistically, treatment with live LGG alone or in combination with anti-PD-1 antibody triggered type I interferon (IFN) production in DCs, enhancing the cross-priming of antitumour CD8+ T cells. In DCs, cyclic GMP-AMP synthase (cGAS)/stimulator of IFN genes (STING) was required for IFN-β induction in response to LGG, as evidenced by the significant decrease in IFN-β levels in cGAS or STING-deficient DCs. LGG induces IFN-β production via the cGAS/STING/TANK binding kinase 1/interferon regulatory factor 7 axis in DCs. CONCLUSION: Our findings have offered valuable insight into the molecular mechanisms of live LGG-mediated antitumour immunity and establish an empirical basis for developing oral administration of live LGG as a combination agent with ICB for cancer therapies.
引用
- Si W, Liang H, Bugno J, et al. Lactobacillus rhamnosus GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade. Gut. 2021. PMID: 33685966. doi:10.1136/gutjnl-2020-323426
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。